JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120868

Niclosamide, STAT3 inhibitor

Be the first to review this product! Submit a review

|

(2 Publications)

MW 327.12 g/mol, Purity >95%. Antihelminthic, anticancer and protonophric agent. STAT3 inhibitor (IC50 = 0.25 μM). Shown to inhibit a number of downstream signaling pathways including mTORC1, Wnt/β-catinin, NF-κB, notch and ROS.
1 Images
Chemical Structure - Niclosamide, STAT3 inhibitor (AB120868)
  • Chemical Structure

Lab

Chemical Structure - Niclosamide, STAT3 inhibitor (AB120868)

2D chemical structure image of ab120868, Niclosamide, STAT3 inhibitor

Key facts

CAS number

50-65-7

Purity

>95%

Form

Solid

form

Molecular weight

327.12 g/mol

Molecular formula

C<sub>1</sub><sub>3</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>

Nature

Synthetic

Solubility

Soluble in ethanol to 0.5 mg/ml

Biological description

Antihelminthic, anticancer and protonophric agent. STAT3 inhibitor (IC50 = 0.25 μM). Shown to inhibit a number of downstream signaling pathways including mTORC1, Wnt/β-catinin, NF-κB, notch and ROS.

Canonical smiles

OC1=C(C(NC2=CC=C([N+]([O-])=O)C=C2CL)=O)C=C(CL)C=C1

IUPAC Name

5-Chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenzamide

style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column
style
left-column
style
left-column

Product protocols

style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

ACS omega 7:3293-3311 PubMed35128241

2022

Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors.

Applications

Unspecified application

Species

Unspecified reactive species

Ramon Martinez,Weiliang Huang,Heather Buck,Samantha Rea,Amy E Defnet,Maureen A Kane,Paul Shapiro

BMC complementary medicine and therapies 21:161 PubMed34078370

2021

Cryptolepine inhibits hepatocellular carcinoma growth through inhibiting interleukin-6/STAT3 signalling.

Applications

Unspecified application

Species

Unspecified reactive species

Seth A Domfeh,Patrick W Narkwa,Osbourne Quaye,Kwadwo A Kusi,Gordon A Awandare,Charles Ansah,Alimatu Salam,Mohamed Mutocheluh
View all publications
style
left-column
style
left-column
style
right-column

Complementary Products

Biochemicals

AB120952

Stattic, STAT3 inhibitor

Functional Studies - Stattic, STAT3 inhibitor (AB120952)

  • 4
  • 1
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB7817

Anti-alpha smooth muscle Actin antibody [1A4]

KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-alpha smooth muscle Actin antibody [1A4] (AB7817)

  • 5
  • 105
Primary Antibodies

AB26

Anti-p53 antibody [PAb 240]

KO Validated|Lab Essentials

Western blot - Anti-p53 antibody [PAb 240] (AB26)

  • 4
  • 56

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com